Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B99 first-line extensive-stage small cell lung cancer platform study
2023-506538-56-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial in small cell lung cancer (SCLC) comparing Keytruda + lenvatinib + etoposide + platinum, Keytruda + MK-4830 + etoposide + platinum and Keytruda + boserolimab + etoposide + platinum (3 arms). Primary endpoints: Objective Response Rate and Six-month Progression-Free Survival. Started Aug 2021; status: completed.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2023-506538-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506538-56-00.